Intelligent Bio Solutions Inc. logo

Intelligent Bio Solutions Inc.(INBS)

upturn advisory logo
ADVISORIES YOU CAN VERIFY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$1.95
09/18/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close

Advisory Performance History (Simulated)Advisory Performance History info

Upturn Advisory & Investor View for INBS

09/18/2026: INBS (1-star) is currently NOT-A-BUY. Pass it for now.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Price Behavior

Steep Decline
PRICE PATH

Steep Decline

The stock price has dropped sharply with strong downward pressure.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit -64.31%
Avg. Invested days 11
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 09/18/2026

Upturn Scorecard

Upturn Star Rating

INBS receives a 3-star rating, supported by solid analyst coverage. The rating is constrained by soft unit economics, and weak price momentum.

Company Fundamentals

INBS has moderate overall fundamentals (3 stars), with soft financial health, moderate growth momentum, and moderate ownership. In FY2026 versus FY2025, strong revenue growth (+38.1%) is partially offset by negative earnings growth (-17.6%), soft cash generation (FCF margin -285.9%), soft profitability (net margin -294.9%).

Financial Health Rating

INBS's financial health is supported by moderate liquidity, including working-capital and asset support (WC/assets 18.2%). Operating efficiency is soft (2 stars), which helps explain the 2-star overall score.

Growth Momentum Score

Revenue growth is INBS's strongest growth driver at +38.1% FY2026 versus FY2025 (strong, 5 stars). By comparison, while earnings growth (-17.6%, negative) and free-cash-flow growth (-21.6%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

Institutional ownership is 5.5% and approximately 88.5% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 2.73% provides only moderate management-shareholder alignment.

Top 5 Institutional Investors

Armistice Capital, LLC 4.31%
Alyeska Investment Group, L.P. 1.26%
Geode Capital Management, LLC 0.95%
Vanguard Capital Management, LLC 0.19%
Vanguard Fiduciary Trust Co 0.13%

Unit Economics (Per $1K Revenue)

INBS generates approximately $486 of gross profit, $-2,991 of operating income, and $-2,859 of free cash flow for every $1,000 of revenue. Based on FY2026 results. Strong cash conversion and healthy margins support the rating, although capital efficiency remains below the highest tier.

Economic Dimensions

Effective Tax Rate: 0.30%

Quantitative Style Profile

INBS has a liquid profile. Weak momentum is the primary drawback, while elevated volatility.

Style Classification

Quality Focused

Value-OrientedHigh VolatilitySmall / Mid Cap RiskHighly Liquid / Institution-Friendly

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 6.47M USD
Price to earnings Ratio -
1Y Target Price 12
Price to earnings Ratio -
1Y Target Price 12
Volume (30-day avg) 259.2K shares
Beta 4.25
52 Weeks Range 1.52 - 24.90
Updated Date 09/19/2026
52 Weeks Range 1.52 - 24.90
Updated Date 09/19/2026
Dividends yield (FY) -
Basic EPS (TTM) -8.44

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Advertisement

Valuation

Trailing PE -
Forward PE -
Enterprise Value 4.29M
Price to Sales(TTM) 1.53
Enterprise Value 4.29M
Price to Sales(TTM) 1.53
Enterprise Value to Revenue 1.02
Enterprise Value to EBITDA -0.91
Shares Outstanding 3.32M
Shares Floating 2.94M
Shares Outstanding 3.32M
Shares Floating 2.94M
Percent Insiders 2.73
Percent Institutions 5.47

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

About Intelligent Bio Solutions Inc.

Exchange NASDAQ
Headquarters New York, NY, United States
IPO Launch date 2020-12-23
President & CEO Mr. Harry Simeonidis
Sector Healthcare
Industry Medical Devices
Full time employees 59
Full time employees 59

Intelligent Bio Solutions Inc., a medical technology company, focused on developing and delivering non-invasive testing, and screening solutions in Asia Pacific, the United States, the United Kingdom, and internationally. The company operates intelligent fingerprinting drug screening system, a platform to analyze fingerprint sweat analysis to detect drugs abuse; and biosensor platform. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022. Intelligent Bio Solutions Inc. was incorporated in 2016 and is headquartered in New York, New York.